Recovery Profiles of Remifentanil-based Regimen for Cardiac Surgery

Overview

Backgrounds: Monitoring of Bispectral index (BIS) has been regarded as useful to determine the degree of intraoperative hypnosis. Major factors of postoperative recovery after cardiac surgery include patient's recovery in cognitive function from the postoperative residual effects of anesthetics, such as opioids and sedatives, administered during intraoperative period. Therefore employing anesthetic regimens which can provide earlier recovery in cognitive function would be beneficial in facilitating fast-track cardiac surgery with earlier postoperative extubation and discharge from the intensive care unit (ICU). Previous investigations suggested efficacy of BIS in evaluating the degree of postoperative hypnosis in the ICU. The present study compares the time for reaching BIS greater than 80 after using 2 different anesthesia regimens for cardiac surgery, remifentanil-based regimen and sevoflurane-sufentanil balanced regimen. Analyzing the changes immediately after cardiac surgery would be useful to determine the degree of patient's postoperative emergence. Materials and Methods: During study period, patients undergoing elective cardiac surgery in Konkuk University Medical Center are randomly assigned to get remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60 (Group R) or sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) balanced regimen in Group S. All patients get intravenous patient controlled anesthesia consisting of alfentanyl and ondansetron after surgery. Supplemental remifentanil 0.25-0.3 mcg/kg/min is administered during postoperative 2 hours in Group R. As a primary objective, inter-group difference in the time for achieving BIS greater than 80 is determined.

Full Title of Study: “Recovery Profiles of Remifentanil-based vs. Sevoflurane-sufentanil Combined Regimen for Cardiac Surgery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2016

Interventions

  • Drug: remifentanil-based
  • Drug: sevoflurane-sufentanil balanced

Arms, Groups and Cohorts

  • Active Comparator: remifentanil-based
    • remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60
  • Placebo Comparator: sevoflurane-sufentanil balanced
    • balanced sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) regimen

Clinical Trial Outcome Measures

Primary Measures

  • Time to reach BIS > 80
    • Time Frame: 1 minute
    • Time to reach BIS > 80 after surgery

Secondary Measures

  • Extubation time
    • Time Frame: 1 minute
    • Time to perform extubation after surgery

Participating in This Clinical Trial

Inclusion Criteria

  • patients undergoing elective coronary artery bypass surgery Exclusion Criteria:

  • combined valve surgery – preoperative intraaortic balloon pumping – preoperative low cardiac output syndrome – chronic obstructive pulmonary disease

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Konkuk University Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Tae-Yop Kim, MD PhD, Professor of Anesthesiology – Konkuk University Medical Center
  • Overall Official(s)
    • Tae-Yop Kim, MD, PhD, Principal Investigator, Konkuk University Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.